Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,394 result(s) found. Displaying page 2,171 of 2,220.
    EudraCT Number: 2020-000649-16 Sponsor Protocol Number: PRV-015-002b Start Date*: 2021-04-06
    Sponsor Name:Provention Bio, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a...
    Medical condition: Celiac Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10007864 Celiac disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-002441-18 Sponsor Protocol Number: D6582C00001 Start Date*: 2022-10-27
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa Randomised, Double-Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    26.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) ES (Ongoing) NL (Completed) IT (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001923-30 Sponsor Protocol Number: TN-20 Start Date*: 2016-09-26
    Sponsor Name:TRIALNET COORDINATING CENTER AT THE UNIVERSITY OF SOUTH FLORIDA
    Full Title: Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10066284 Diabetes prophylaxis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003851-12 Sponsor Protocol Number: 20968 Start Date*: 2020-06-25
    Sponsor Name:Bayer AG
    Full Title: Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
    Medical condition: Neovascular Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) LV (Completed) PT (Completed) EE (Completed) AT (Completed) FR (Completed) SK (Completed) BG (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002644-23 Sponsor Protocol Number: MB_PDT_1 Start Date*: 2020-07-23
    Sponsor Name:Dept. of Dermatology, Zealand University Hospital, Roskilde
    Full Title: Photodynamic therapy of antifungal resistant dermatophytes
    Medical condition: Competent patients over 18 years old with mycological verified antifungal resistant dermatophytosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10043870 Tinea infections HLT
    20.0 10021881 - Infections and infestations 10043868 Tinea cruris PT
    20.0 10021881 - Infections and infestations 10060889 Tinea infection PT
    21.1 10021881 - Infections and infestations 10043873 Tinea pedis PT
    20.0 10021881 - Infections and infestations 10049591 Tinea imbricata PT
    20.0 10021881 - Infections and infestations 10067197 Tinea manuum PT
    20.0 10021881 - Infections and infestations 10043872 Tinea NOS LLT
    20.1 10021881 - Infections and infestations 10043869 Tinea infection NOS LLT
    20.0 10021881 - Infections and infestations 10043867 Tinea corporis LLT
    20.0 10021881 - Infections and infestations 10043864 Tinea LLT
    20.0 10021881 - Infections and infestations 10053041 Tinea trichophytina cruris LLT
    20.0 10021881 - Infections and infestations 10073383 Tinea of hand LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006788-11 Sponsor Protocol Number: NBI-827104-CSWS2025 Start Date*: 2022-03-25
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep
    Medical condition: Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003426-32 Sponsor Protocol Number: DCOne-002 Start Date*: 2017-12-11
    Sponsor Name:DCprime bv
    Full Title: AN INTERNATIONAL, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DIFFERENT VACCINATION REGIMENS OF IMMUNOTHERAPY WITH ALLOGENEIC DENDRITIC CELLS, DCP-001, IN PATIENTS WIT...
    Medical condition: The medical condition investigated are patients with acute myeloid leukemia in complete remission with persistent minimal residual disease and as such are at high risk of relapse.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) NO (Completed) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004045-25 Sponsor Protocol Number: GBT440-034 Start Date*: 2018-04-17
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000903-26 Sponsor Protocol Number: GBT440-032 Start Date*: 2022-02-02
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2)
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004482-89 Sponsor Protocol Number: GBG93 Start Date*: 2018-01-08
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTI-CENTER PHASE IV STUDY EVALUATING PALBOCICLIB PLUS ENDOCRINE TREATMENT VERSUS A CHEMOTHERAPY-BASED TREATMENT STRATEGY IN PATIENTS WITH HORMONE RECEPTOR POSITIVE / HER...
    Medical condition: Metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072737 Advanced breast cancer LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005037-16 Sponsor Protocol Number: 217095 Start Date*: 2022-05-17
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-1 (...
    Medical condition: Chronic Rhinosinusitis with Nasal Polyps
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10080060 Chronic rhinosinusitis with nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-002012-31 Sponsor Protocol Number: CNTO1959PSA2003 Start Date*: 2021-10-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab and Golimumab Combination Therapy in Participants with Active Ps...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed) DK (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003109-92 Sponsor Protocol Number: CRFSPN004 Start Date*: 2020-03-20
    Sponsor Name:Trinity College Dublin
    Full Title: Ketamine as an adjunctive therapy for Major Depression (2) - a randomised controlled trial
    Medical condition: Major Depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000711-76 Sponsor Protocol Number: N/A Start Date*: 2020-07-13
    Sponsor Name:Alexander Egeberg
    Full Title: Efficacy of roflumilast in the treatment of psoriasis – a randomised controlled trial
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005712-62 Sponsor Protocol Number: CO43613 Start Date*: 2022-06-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF...
    Medical condition: Squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001137-41 Sponsor Protocol Number: 666 Start Date*: 2018-06-26
    Sponsor Name:Hvidovre Hospital. Dep of Respiratory Medicine
    Full Title: Use of Omalizumab will increase the pregnancy rate, proof of concept study, where women with asthma and infertility will be treated three times with weight and IgE balanced dosis at the sixth day o...
    Medical condition: infertility within female asthma patients as a result of systemic inflamation.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-005331-78 Sponsor Protocol Number: ACT16849 Start Date*: 2022-09-06
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Phase 2 non-randomized, open-label, multi-cohort, multi center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participa...
    Medical condition: Pleural mesothelioma Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000260-22 Sponsor Protocol Number: PKM16982 Start Date*: 2025-07-18
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: A multi-center, single-arm study to investigate the pharmacokinetics and safety of dupilumab in male and female participants ≥2 years to <12 years of age with uncontrolled chronic spontaneous urti...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-002150-91 Sponsor Protocol Number: ACT16941 Start Date*: 2022-01-31
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Phase 2 non-randomized, open-label, multi-cohort, multicenter study assessing the clinical benefit of SAR444245 (THOR-707) with or without other anticancer therapies for the treatment of adults and...
    Medical condition: Classic Hodgkin Lymphoma Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020206 Hodgkin's disease PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002123-11 Sponsor Protocol Number: HUIS-04-2020 Start Date*: 2020-05-07
    Sponsor Name:Tatiana Cobo Ibáñez [...]
    1. Tatiana Cobo Ibáñez
    2. Gemma María Mora Ortega
    3. Gonzalo Serralta San Martín
    Full Title: EFFICACY OF CYCLOSPORINE IN THE TREATMENT OF COVID-19 PNEUMONIA: A RANDOMIZED CONTROLLED TRIAL.
    Medical condition: COVID-19 PNEUMONIA
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084383 Novel COVID-19-infected pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 28 19:23:57 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA